Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

Mark A. Socinski; Coleman Obasaju; David Gandara; Fred R. Hirsch; Philip Bonomi; Paul A. Bunn; Edward S. Kim; Corey J. Langer; Ronald B. Natale; Silvia Novello; Luis Paz-Ares; Maurice Pérol; Martin Reck; Suresh S. Ramalingam; Craig H. Reynolds; David R. Spigel; Heather Wakelee; Nick Thatcher

doi:10.1016/j.jtho.2017.11.111

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

Mark A. Socinski, Coleman Obasaju, David Gandara, Fred R. Hirsch, Philip Bonomi, Paul A. Bunn, Edward S. Kim, Corey J. Langer, Ronald B. Natale, Silvia Novello, Luis Paz-Ares, Maurice Pérol, Martin Reck, Suresh S. Ramalingam, Craig H. Reynolds, David R. Spigel, Heather Wakelee, Nick Thatcher

Research output: Contribution to journal › Review article › peer-review

135 Scopus citations

Abstract

Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of NSCLC that is challenging to treat because of specific clinicopathologic characteristics, which include older age, advanced disease at diagnosis, comorbid diseases, and the central location of tumors. These characteristics have a bearing on treatment outcomes in advanced SqCLC, resulting in a median survival approximately 30% shorter than for patients with other NSCLC subtypes. In the context of the specific features of SqCLC, we review challenges of treating SqCLC and the current guideline-recommended treatments for advanced (metastatic) SqCLC in different patient subpopulations. We also evaluate recently approved treatment options, including necitumumab, afatinib, nivolumab, pembrolizumab, and atezolizumab; discuss the survival benefits associated with each agent in the advanced SqCLC population; and propose a treatment algorithm incorporating these agents for this challenging-to-treat disease. Lastly, we review the preliminary clinical evidence for immunotherapy agents in development for advanced NSCLC.

Original language	English
Pages (from-to)	165-183
Number of pages	19
Journal	Journal of Thoracic Oncology
Volume	13
Issue number	2
DOIs	https://doi.org/10.1016/j.jtho.2017.11.111
State	Published - Feb 2018
Externally published	Yes

Keywords

Non–small cell lung cancer
Squamous cell lung cancer
Treatment algorithm
Treatment guidelines

Access to Document

10.1016/j.jtho.2017.11.111

Cite this

Socinski, M. A., Obasaju, C., Gandara, D., Hirsch, F. R., Bonomi, P., Bunn, P. A., Kim, E. S., Langer, C. J., Natale, R. B., Novello, S., Paz-Ares, L., Pérol, M., Reck, M., Ramalingam, S. S., Reynolds, C. H., Spigel, D. R., Wakelee, H., & Thatcher, N. (2018). Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. Journal of Thoracic Oncology, 13(2), 165-183. https://doi.org/10.1016/j.jtho.2017.11.111

@article{f0ee07bd037f4b8f9db30319aa47d770,

title = "Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer",

abstract = "Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of NSCLC that is challenging to treat because of specific clinicopathologic characteristics, which include older age, advanced disease at diagnosis, comorbid diseases, and the central location of tumors. These characteristics have a bearing on treatment outcomes in advanced SqCLC, resulting in a median survival approximately 30% shorter than for patients with other NSCLC subtypes. In the context of the specific features of SqCLC, we review challenges of treating SqCLC and the current guideline-recommended treatments for advanced (metastatic) SqCLC in different patient subpopulations. We also evaluate recently approved treatment options, including necitumumab, afatinib, nivolumab, pembrolizumab, and atezolizumab; discuss the survival benefits associated with each agent in the advanced SqCLC population; and propose a treatment algorithm incorporating these agents for this challenging-to-treat disease. Lastly, we review the preliminary clinical evidence for immunotherapy agents in development for advanced NSCLC.",

keywords = "Non–small cell lung cancer, Squamous cell lung cancer, Treatment algorithm, Treatment guidelines",

author = "Socinski, {Mark A.} and Coleman Obasaju and David Gandara and Hirsch, {Fred R.} and Philip Bonomi and Bunn, {Paul A.} and Kim, {Edward S.} and Langer, {Corey J.} and Natale, {Ronald B.} and Silvia Novello and Luis Paz-Ares and Maurice P{\'e}rol and Martin Reck and Ramalingam, {Suresh S.} and Reynolds, {Craig H.} and Spigel, {David R.} and Heather Wakelee and Nick Thatcher",

note = "Publisher Copyright: {\textcopyright} 2018 International Association for the Study of Lung Cancer",

year = "2018",

month = feb,

doi = "10.1016/j.jtho.2017.11.111",

language = "English",

volume = "13",

pages = "165--183",

journal = "Journal of Thoracic Oncology",

issn = "1556-0864",

publisher = "International Association for the Study of Lung Cancer",

number = "2",

}

Socinski, MA, Obasaju, C, Gandara, D, Hirsch, FR, Bonomi, P, Bunn, PA, Kim, ES, Langer, CJ, Natale, RB, Novello, S, Paz-Ares, L, Pérol, M, Reck, M, Ramalingam, SS, Reynolds, CH, Spigel, DR, Wakelee, H & Thatcher, N 2018, 'Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer', Journal of Thoracic Oncology, vol. 13, no. 2, pp. 165-183. https://doi.org/10.1016/j.jtho.2017.11.111

TY - JOUR

T1 - Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

AU - Socinski, Mark A.

AU - Obasaju, Coleman

AU - Gandara, David

AU - Hirsch, Fred R.

AU - Bonomi, Philip

AU - Bunn, Paul A.

AU - Kim, Edward S.

AU - Langer, Corey J.

AU - Natale, Ronald B.

AU - Novello, Silvia

AU - Paz-Ares, Luis

AU - Pérol, Maurice

AU - Reck, Martin

AU - Ramalingam, Suresh S.

AU - Reynolds, Craig H.

AU - Spigel, David R.

AU - Wakelee, Heather

AU - Thatcher, Nick

PY - 2018/2

Y1 - 2018/2

N2 - Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of NSCLC that is challenging to treat because of specific clinicopathologic characteristics, which include older age, advanced disease at diagnosis, comorbid diseases, and the central location of tumors. These characteristics have a bearing on treatment outcomes in advanced SqCLC, resulting in a median survival approximately 30% shorter than for patients with other NSCLC subtypes. In the context of the specific features of SqCLC, we review challenges of treating SqCLC and the current guideline-recommended treatments for advanced (metastatic) SqCLC in different patient subpopulations. We also evaluate recently approved treatment options, including necitumumab, afatinib, nivolumab, pembrolizumab, and atezolizumab; discuss the survival benefits associated with each agent in the advanced SqCLC population; and propose a treatment algorithm incorporating these agents for this challenging-to-treat disease. Lastly, we review the preliminary clinical evidence for immunotherapy agents in development for advanced NSCLC.

AB - Squamous cell lung cancer (SqCLC) is a distinct histologic subtype of NSCLC that is challenging to treat because of specific clinicopathologic characteristics, which include older age, advanced disease at diagnosis, comorbid diseases, and the central location of tumors. These characteristics have a bearing on treatment outcomes in advanced SqCLC, resulting in a median survival approximately 30% shorter than for patients with other NSCLC subtypes. In the context of the specific features of SqCLC, we review challenges of treating SqCLC and the current guideline-recommended treatments for advanced (metastatic) SqCLC in different patient subpopulations. We also evaluate recently approved treatment options, including necitumumab, afatinib, nivolumab, pembrolizumab, and atezolizumab; discuss the survival benefits associated with each agent in the advanced SqCLC population; and propose a treatment algorithm incorporating these agents for this challenging-to-treat disease. Lastly, we review the preliminary clinical evidence for immunotherapy agents in development for advanced NSCLC.

KW - Non–small cell lung cancer

KW - Squamous cell lung cancer

KW - Treatment algorithm

KW - Treatment guidelines

UR - http://www.scopus.com/inward/record.url?scp=85042408205&partnerID=8YFLogxK

U2 - 10.1016/j.jtho.2017.11.111

DO - 10.1016/j.jtho.2017.11.111

M3 - Review article

C2 - 29175116

AN - SCOPUS:85042408205

SN - 1556-0864

VL - 13

SP - 165

EP - 183

JO - Journal of Thoracic Oncology

JF - Journal of Thoracic Oncology

IS - 2

ER -

Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer

Abstract

Keywords

Access to Document

Fingerprint

Cite this